The Little Mix singer said she auditioned for "The X Factor" just months after leaving the hospital, where she was treated ...

(Reuters) -Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying ...

Novo Nordisk (NYSE:NVO) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 15, Novo ...

The clinical-stage biotech, closely watched by some because of its investigational weight-loss drug VK2735, saw its share ...

Dow Jones Top Company Headlines at 9 PM ET: SoftBank Invests $2 Billion in Intel as U.S. Considers Taking 10% Stake in Chip Maker | BHP ... SoftBank Invests $2 Billion in Intel as U.S. Considers ...

Viking Therapeutics offers a speculative opportunity, driven by its promising obesity drug pipeline. Click here to read more ...

The detention facility operator named Patrick Swindle as its next chief executive officer, succeeding long-time executive Damon Hininger, who will continue at the company under a transition agreement.

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Live Updates Live Coverage Has Ended Monday Wrap-up 4:11 pm The Vanguard S&P 500 ETF closed at 591.36 Monday, down 0.04%.

The FDA has approved Novo Nordisk’s Wegovy to treat metabolic associated steatohepatitis, or MASH, in adults who have excessive scar tissue in the liver. MASH is a serious liver condition linked to ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...